Maintaining Investments in New Innovation Act
See what this could mean for your district
Save your district in Account to view district-specific context for this bill.
Bill details
Bill overview
A neutral overview based on official congressional sources.
Introduced in House
Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)
Related votes
Roll calls that reference this bill in official data.
Primary sources
Official links to verify details. No interpretation.